Reuters logo
BRIEF-Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075
October 11, 2017 / 12:19 PM / 8 days ago

BRIEF-Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075

Oct 11 (Reuters) - Mabvax Therapeutics Holdings Inc

* Mabvax Therapeutics initiates patient enrollment in a phase 1 trial for MVT-1075, a new radioimmunotherapy treatment for advanced pancreatic, colon and lung cancers

* Mabvax Therapeutics Holdings Inc - ‍Plans to announce topline interim results before year end from study​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below